The Role of CYP1B1 in the Recurrence of Head and Neck Cancer
CYP1B1在头颈癌复发中的作用
基本信息
- 批准号:8201095
- 负责人:
- 金额:$ 5.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-12-01 至 2013-11-30
- 项目状态:已结题
- 来源:
- 关键词:8-hydroxy-2&apos-deoxyguanosineAccountingAdultAdverse effectsAgeAlcohol consumptionAlcoholsAllelesApoptosisBeliefBenzo(a)pyreneBiologicalBiological AssayBiological MarkersBiological MarkersCarcinogensCell ProliferationCellsCharacteristicsCountryCultured CellsCytochrome P450DNA DamageDataDevelopmentDiagnosisDiseaseEarly DiagnosisEnzymesEpitheliumEstrogensEthanolExposure toFemaleGenderGenesGenetic PolymorphismGenotypeHead and Neck CancerHead and Neck Squamous Cell CarcinomaHead and neck structureHormonesHumanHuman EngineeringIncidenceIndividualInterventionInvadedMalignant NeoplasmsMessenger RNAMetabolismMolecular TargetOperative Surgical ProceduresOral LeukoplakiaOrganPathway interactionsPatientsPlayPremalignantPreventionProteinsRecurrenceRiskRisk FactorsRoleSmokingTimeTissue SampleTissuesTobaccoTobacco smokeTobacco smokingTobacco useTongue Squamous Cell CarcinomaTranslatingTreatment Protocolsagedalternative treatmentbasecancer typecarcinogenesiscell typedisease phenotypedrinkinghigh risklung CarcinomamRNA Expressionmortalityoral tissueoverexpressionoxidative damageproblem drinkerpublic health relevanceresponsetumor
项目摘要
DESCRIPTION (provided by applicant): Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer. Its incidence increased 60% recently in adults age 40 or less. Mortality among HNSCC patients is very high, often due to recurrence of primary disease. Major risk factors for HNSCC include tobacco and alcohol use. Data from this group and others suggest that estrogens may also contribute to the development of HNSCCs. The tobacco smoke carcinogen benzo(a)pyrene (B(a)P), ethanol from alcoholic drinks and the female hormone estrogen are all metabolized by cytochrome P450 (CYP) 1B1 to potentially carcinogenic metabolites. The hypothesis of the proposed studies is that a polymorphism in CYP1B1 (CYP1B1*2) confers a more aggressive disease phenotype and a greater risk of recurrence of HNSCC. Rationale for the role of CYP1B1 in HNSCC is provided by preliminary data that suggest that 1) the CYP1B1*2 polymorphism, which results in elevated basal expression of CYP1B1, confers increased risk of recurrence for HNSCC; 2) CYP1B1 protein is elevated in human HNSCCs as compared to non-neoplastic epithelium and 3) ethanol and estrogen induce CYP1B1 mRNA levels. In Aim 1, the effect of overexpressing a high-risk CYP1B1*2 allele vs wild type on selected biomarkers (cell proliferation, anchorage independence, invasion, survival, apoptosis and oxidative damage) will be evaluated in cultured premalignant oral leukoplakia (MSK-Leuki) cells following exposure to B(a)P, ethanol and estrogen. Results from studies in MSK-Leuki cells will be translated to an analysis of oral tissue from HNSCC patients in Aim 2. Patients with HNSCC will be genotyped for CYP1B1 (using TaqMan(R) assays) and the effect of the CYP1B1*2 allele on tumor recurrence will be examined in patients stratified by smoking, alcohol use and gender. Sections from tissue blocks from patients will be evaluated immunohistochemically for the level of biomarkers (apoptosis, proliferation and oxidative damage). The association of biomarker levels with CYP1B1 genotype will be investigated. The resulting data are anticipated to significantly enhance our understanding of the function of CYP1B1 in the recurrence of HNSCC and aid in determining the contribution of exposures to tobacco, estrogen and/or alcohol to recurrence in individuals carrying the high-risk CYP1Br2 allele.
PUBLIC HEALTH RELEVANCE: Our findings suggest for the first time that a common polymorphism in the CYP1B1 gene increases risk of recurrence of HNSCC. Successful confirmation of this belief will greatly help us to more accurately predict who is at highest risk for recurrence of HNSCC, and aid in the development of new treatments and markers for the early detection and prevention of this devastating disease.
描述(由申请人提供):头颈部鳞状细胞癌(HNSCC)是第六种最常见的癌症类型。在40岁以下的成年人中,其发病率最近增加了60%。HNSCC患者的死亡率非常高,通常是由于原发病的复发。HNSCC的主要危险因素包括吸烟和饮酒。来自这个组和其他人的数据表明,雌激素也可能有助于HNSCCs的发展。烟草烟雾致癌物苯并(a)芘(B(a)P)、酒精饮料中的乙醇和雌性激素雌激素都被细胞色素P450(CYP)1B 1代谢成潜在致癌代谢物。拟议研究的假设是,CYP 1B 1(CYP 1B 1 *2)的多态性赋予了更具侵袭性的疾病表型和更大的HNSCC复发风险。初步数据提供了CYP 1B 1在HNSCC中作用的依据,这些数据表明:1)CYP 1B 1 *2多态性导致CYP 1B 1基础表达升高,导致HNSCC复发风险增加; 2)与非肿瘤上皮相比,CYP 1B 1蛋白在人HNSCC中升高; 3)乙醇和雌激素诱导CYP 1B 1 mRNA水平。在目的1中,将在暴露于B(a)P、乙醇和雌激素后,在培养的癌前口腔白斑(MSK-Leuki)细胞中评价过表达高风险CYP 1B 1 *2等位基因相对于野生型对所选生物标志物(细胞增殖、锚定独立性、侵袭、存活、凋亡和氧化损伤)的影响。MSK-Leuki细胞研究的结果将转化为目标2中HNSCC患者口腔组织的分析。将对HNSCC患者进行CYP 1B 1基因分型(使用TaqMan(R)测定),并在按吸烟、饮酒和性别分层的患者中检查CYP 1B 1 *2等位基因对肿瘤复发的影响。将对来自患者的组织块的切片进行生物标志物(细胞凋亡、增殖和氧化损伤)水平的化学评价。将研究生物标志物水平与CYP 1B 1基因型的相关性。预计所得数据将显著增强我们对CYP 1B 1在HNSCC复发中的功能的理解,并有助于确定暴露于烟草、雌激素和/或酒精对携带高危CYP 1Br 2等位基因的个体复发的贡献。
公共卫生相关性:我们的研究结果首次表明,CYP 1B 1基因的常见多态性增加了HNSCC复发的风险。这一信念的成功证实将极大地帮助我们更准确地预测谁是HNSCC复发的最高风险,并有助于开发新的治疗方法和标记物,以早期发现和预防这种毁灭性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ekaterina G. Shatalova其他文献
Ekaterina G. Shatalova的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ekaterina G. Shatalova', 18)}}的其他基金
The Role of CYP1B1 in the Recurrence of Head and Neck Cancer
CYP1B1在头颈癌复发中的作用
- 批准号:
8392103 - 财政年份:2010
- 资助金额:
$ 5.68万 - 项目类别:
The Role of CYP1B1 in the Recurrence of Head and Neck Cancer
CYP1B1在头颈癌复发中的作用
- 批准号:
7802603 - 财政年份:2010
- 资助金额:
$ 5.68万 - 项目类别:
相似海外基金
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
- 批准号:
10305569 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
- 批准号:
10488244 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10305565 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10488242 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10488237 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10305568 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
RUI: Chemical Investigations into the Bioactivity of the DNA Lesion 8-Oxo-2'-deoxyguanosine
RUI:DNA 损伤 8-Oxo-2-脱氧鸟苷生物活性的化学研究
- 批准号:
1903855 - 财政年份:2019
- 资助金额:
$ 5.68万 - 项目类别:
Standard Grant
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2017
- 资助金额:
$ 5.68万 - 项目类别:
Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2015
- 资助金额:
$ 5.68万 - 项目类别:
Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2014
- 资助金额:
$ 5.68万 - 项目类别:
Discovery Grants Program - Individual